CAS: 164332-88-1; Tert-Butyl (2-(2-Bromoethoxy)Ethyl)Carbamate

该化合物是一种双功能试剂,由多乙基甘醇(PEG2)空间仪连接,由一个受波克保护的矿质组和终端溴化二苯组成. Boc组提供多步骤合成中选择性脱保护的正方形,而溴则作为核生殖替代或交叉反应的活性处理器.PEG2空间仪可增强溶性和灵活性,使其在药物发现,生物合成和物质科学应用中发挥作用.在一系列条件下和与共同保护群体战略兼容性下,其稳定性使其成为构建复杂分子结构的多功能中间体.该化合物通常用于化改造,链接合成和功能化聚合聚合物的准备工作.

结构式图片

相似化合物

165963-71-3 1076199-21-7 1392499-32-9

欧盟法规

C&L通报

上下游产品

2-(2-Boc-氨基乙氧基)乙醇 2-(2-Tert-Butyloxycarbonylaminoethoxy)Ethanol 139115-91-6

合成工艺路线路线简述

  • 合成目标产物 Br-Peg1-Nhboc 主要起始原料 2-(2-Boc-Aminoethoxy)Ethanol
  • (文献来源)合成步骤主要原料 2-(2-Boc-Aminoethoxy)Ethanol
📜2-(2-Boc-氨基乙氧基)乙醇置于四溴化碳,三苯基膦体系中,用 二氯甲烷 用作溶剂,化学反应 22.0H,以85%的收率获得叔丁氧羰基-二聚乙二醇-溴代
参考文献:通过胍鎓系链的低聚亚苯基亚乙烯基的自组装将二羧酸盐结构信息转换为荧光光学信号
标题:通过胍鎓系链的低聚亚苯基亚乙烯基的自组装将二羧酸盐结构信息转换为荧光光学信号
摘要:尽管自组装已经实现了纳米结构的自发形成,但是分子结构上化学结构信息的纳米表达也可以看作是高精度翻译分子结构信息的工具.我们已经发现,一种新开发的胍盐-拴系的oligophenylenevinylene展品特性的荧光(fl)朝向反应大号-和内消旋-Tartarate,其中,所述不同的自组装模式,称为j-或h型聚合中,根据分子信息涉及编码为化学结构.从这个几何形态差异源自抗与笨拙之间的构象差异大号-和中观-Tartarate.富马酸酯和马来酸酯之间的几何cc键差异可以再现相似的形态差异.在本系统中,二羧酸盐结构信息体现在fl响应的固有阈值浓度,信噪比和最大fl波长中.这些结果表明自组装足够细致,可以感知分子信息中的细微差异,因此证明了自组装对fl感觉系统表达的潜在能力.
Doi:10.1002/chem.201404028

海关参考信息

专利信息


专利号:US-2025129021-A1
优先权日:2023-09-19
标 题:Small molecule protein synthesis modulators
发明人:GYGI DAVID; BAHMANYAR SOGOLE SAMI; HAMANN LAWRENCE
权利人:INTERDICT BIO INC
摘要:The present disclosure provides compounds of the formulae herein (e.g., Formula (I), Formula (V)), and pharmaceutically acceptable salts thereof, which are useful for modulating protein synthesis (e.g., modulating synthesis of BCL-2, MYC, CCND1, MCL-1, ALK, KRAS-G12D). The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, or pharmaceutically acceptable salts thereof, and methods of treating or preventing diseases or disorders (e.g., diseases or disorders associated with BCL-2, MYC, CCND1, MCL-1, ALK, KRAS-G12D) by administering to a subject in need thereof the compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof.

专利号:EP-0575490-B1
优先权日:1991-03-14
标题 :GnRH ANALOGS
发明人:HOEGER CARL A; RIVIER JEAN EDOUARD FREDERIC; THEOBALD PAULA GUESS; PORTER JOHN S; RIVIER CATHERINE LAURE; VALE WYLIE WALKER JR
权利人:SALK INST FOR BIOLOGICAL STUDI
摘要:Peptides which include unnatural amino acids and which inhibit the secretion of gonadotropins by the pituitary gland and inhibit the release of steroids by the gonads. The peptides are analogs of the decapeptide GnRH wherein there is at least one residue of an unnatural amino acid U<*> in the 3-, 5- and/or 6-positions. Such unnatural amino acids are useful in the synthesis of peptides and can be formed after synthesis of the peptide chain. The unnatural amino acid U<*> can have a cyanoguanidino group on the omega carbon atom of the side chain, but preferably has formula U<*> (I) where j is 1 or 2 and R11 is H or an acyl radical having 1 to 6 carbon atoms.

专利号:US-5710249-A
优先权日:1989-10-30
标题 :Amino acids and processes for making peptides using same
发明人:HOEGER CARL A; RIVIER JEAN E F; PORTER JOHN S
权利人:SALK INST FOR BIOLOGICAL STUDI
摘要:Methods of making unnatural amino acids are provided which unnatural amino acids can be incorporated into peptides which either inhibit or promote the secretion of gonadotropins by the pituitary gland and inhibit the release of steroids by the gonads. These unnatural amino acids are useful in the synthesis of peptides and have the formula (a): where W is (CH2) or n is an integer from 1 to 6; j=1, 2 or 3, and preferably, Y is N-CN, X is NH and R2 is alkyl, modified alkyl, alkenyl, alkynyl, aryl or methyl pyridyl. Disclosed are peptides that are analogs of the decapeptide GnRH wherein there is at least one residue of an unnatural amino acid in the 3-, 5-, 6- and/or 8-positions.

专利号:US-5169932-A
优先权日:1989-10-30
标题 :Gnrh analogs
发明人:HOEGER CARL A; RIVIER JEAN E F; THEOBALD PAULA G; PORTER JOHN S; RIVIER CATHERINE L; VALE JR WYLIE W
权利人:SALK INST FOR BIOLOGICAL STUDI
摘要:Peptides which include unnatural amino acides and which either inhibit or promote the secretion of gonadotropins by the pituitary gland and inhibit the release of steroids by the gonads. Administration of an effective amount of such peptides that are GnRH antagonists prevents ovulation of female mammalian eggs and/or the release of steroids by the gonads. The antagonists may be used to treat steroid-dependent tumors, such as prostatic and mammary tumors. The peptides are analogs of the decapeptide GnRH wherein there is at least one residue of an unnatural amino acid in the 3-position, the 5-position, the 6-position and/or the 8-position. Such unnatural amino acids are useful in the synthesis of peptides and have the formula U*: where n is an integer from 1 to 6; Y is N-CN, N-CONHR9, S, O or CH-NO2; R9 is H, Ac, lower alkyl, aromatic or heterocyclic; X is NH, O, S, M1(CHq)pM2 or M1-(CH2)p'-M2(CH2)p''-M3, where M1 is NR10, O, S or CHR3 wherein R3 is methyl, ethyl, propyl, phenyl, pyridinyl, pyrimidinyl or purinyl, q is 1 or 2; p, p' and p'' are integers between O and 6; R10 is H, lower alkyl or the like, and M2 and M3 are M1, COOH, CONH2, COOR3 or CN; R1 is H, alkyl, modified alkyl, alkenyl, alkynyl, aryl or a direct bond to X; R2 is R1, OH, NH2, NHR1, or heterocycle.

专利号:US-5296468-A
优先权日:1989-10-30
标 题:GnRH analogs
发明人:HOEGER CARL A; RIVIER JEAN EDOUARD FREDERIC; THEOBALD PAULA GUESS; PORTER JOHN S; RIVIER CATHERINE LAURE; VALE WYLIE WALKER JR
权利人:SALK INST FOR BIOLOGICAL STUDI
摘要:Peptides which include unnatural amino acids and which either inhibit or promote the secretion of gonadotropins by the pituitary gland and inhibit the release of steroids by the gonads. Administration of an effective amount of such peptides that are GnRH antagonists prevents ovulation of female mammalian eggs and/or the release of steroids by the gonads. The antagonists may be used to treat steroid-dependent tumors, such as prostatic and mammary tumors. The peptides are analogs of the decapeptide GnRH wherein there is at least one residue of an unnatural amino acid in the 3-, 5-, 6- and/or 8-positions. Such unnatural amino acids are useful in the synthesis of peptides and have the formula U*: (* CHEMICAL STRUCTURE *) where W is (CH2)n or (* CHEMICAL STRUCTURE *) n is an integer from 1 to 6; and j=1, 2 or 3. Preferably, either Y is N-CN, X is NH and R2 is alkyl, modified alkyl, alkenyl, alkynyl, aryl or methyl pridyl or (* CHEMICAL STRUCTURE *) where R11 is H or acyl.

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Zhang P, Huang Y, Liu H, Marquez RT, Lu J, Zhao W, Zhang X, Gao X, Li J, Venkataramanan R, Xu L, Li S. A PEG-Fmoc conjugate as a nanocarrier for paclitaxel. Biomaterials. 2014 Aug;35(25):7146-56. doi: 10.1016/j.biomaterials.2014.04.108. Epub 2014 May 22.
2: Salmaso S, Bersani S, Scomparin A, Mastrotto F, Scherpfer R, Tonon G, Caliceti P. Tailored PEG for rh-G-CSF analogue site-specific conjugation. Bioconjug Chem. 2009 Jun;20(6):1179-85. doi: 10.1021/bc9000432.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知